<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978675</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1347</org_study_id>
    <secondary_id>NCI-2021-05725</secondary_id>
    <secondary_id>2020-1347</secondary_id>
    <nct_id>NCT04978675</nct_id>
  </id_info>
  <brief_title>An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer</brief_title>
  <official_title>A Prospective Pilot Study Investigating rhPSMA 7.3 PET/MRI in Detecting Recurrent Disease and Aid in Radiotherapy Planning in Patients With Biochemically Recurrent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective pilot study will assess the feasibility of rh PSMA 7.3 positron emission&#xD;
      tomography/magnetic resonance imaging (PET/MRI) scans in detecting prostate cancer that may&#xD;
      have come back (recurrent) in patients with increasing levels of prostate-specific antigen&#xD;
      (PSA) following prostate surgery (biochemically recurrent). An increase in PSA levels alone&#xD;
      does not tell the doctor where the cancer may be or how much cancer there may be. Imaging&#xD;
      tests, like a bone scan, MRI, and/or computed tomography, are often performed to help the&#xD;
      doctor learn where or how much cancer there is, and how best to treat the cancer. rhPSMA-7.3&#xD;
      is a radioactive tracer agent that when used with PET/MRI imaging may help diagnose and look&#xD;
      for the spread of prostate cancer. Prostate-specific membrane antigen (PSMA) is a protein&#xD;
      that is expressed in prostate cancer and this agent targets the PSMA molecule. Giving rh PSMA&#xD;
      7.3 during PET/MRI may help doctors better find where the cancer may be spreading and how&#xD;
      much of it there is. The results of this trial may also guide in radiotherapy planning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the positive predictive value and detection rate of fluorine F 18 rhPSMA-7.3&#xD;
      (F-18 rhPSMA-7.3) positron emission tomography (PET)/magnetic resonance imaging (MRI) in&#xD;
      detecting recurrent disease in prostate cancer patients with biochemical recurrence.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the change in salvage radiation treatment plan after F-18 rhPSMA-7.3 PET/MRI&#xD;
      imaging.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To assess the feasibility of utilizing the PSMA avid recurrent disease on PET/MRI as an&#xD;
      alignment tool for MR guided radiotherapy (MR linear accelerator [MR-LINAC]).&#xD;
&#xD;
      II. To assess the treatment response in those patients who demonstrate rhPSMA-7.3 avid&#xD;
      disease on the first PET/MRI scan.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive F-18 rhPSMA-7.3 intravenously (IV) and after approximately 60 minutes of&#xD;
      uptake time, will undergo PET/MRI over 60 minutes. Patients with evidence of F-18 rhPSMA-7.3&#xD;
      disease in the first PET/MRI scan undergo a second F-18 rhPSMA-7.3 PET/MRI at 6 months after&#xD;
      the second dose of standard hormonal therapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed up within 7 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2021</start_date>
  <completion_date type="Anticipated">April 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive predictive value (PPV) of F-18 rhPSMA-7.3 positron emission tomography/magnetic resonance imaging (PET/MRI) in detecting recurrent disease</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will be evaluated on both a per-patient and per-region basis. Will estimate the PPV rate and corresponding 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Defined as the proportion of patients with prostate-specific membrane antigen (PSMA) positive results. The association between detection and prostate specific antigen level will be assessed by Wilcoxon rank-sum tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in salvage radiation treatment plan</measure>
    <time_frame>Baseline up to 6 months</time_frame>
    <description>The proportion of patients with major and minor changes will be summarized.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Biochemically Recurrent Prostate Carcinoma</condition>
  <condition>Localized Prostate Carcinoma</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (F-18 rhPSMA-7.3, PET/MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive F-18 rhPSMA-7.3 IV and after approximately 60 minutes of uptake time, will undergo PET/MRI over 60 minutes. Patients with evidence of F-18 rhPSMA-7.3 disease in the first PET/MRI scan undergo a second F-18 rhPSMA-7.3 PET/MRI at 6 months after the second dose of standard hormonal therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorine F 18 rhPSMA-7.3</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (F-18 rhPSMA-7.3, PET/MRI)</arm_group_label>
    <other_name>(18F)-rhPSMA-7.3</other_name>
    <other_name>18F-rhPSMA-7.3</other_name>
    <other_name>18FrhPSMA-7.3</other_name>
    <other_name>F-18-rhPSMA-7.3</other_name>
    <other_name>Fluorine F 18 radiohybrid PSMA-7.3</other_name>
    <other_name>Fluorine-18 rhPSMA-7.3</other_name>
    <other_name>rhPSMA-7.3 (18F)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic (F-18 rhPSMA-7.3, PET/MRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic (F-18 rhPSMA-7.3, PET/MRI)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is male and aged &gt; 18 years old&#xD;
&#xD;
          -  History of localized adenocarcinoma of the prostate status post (s/p) radical&#xD;
             prostatectomy&#xD;
&#xD;
          -  An initial elevated PSA &gt;= 0.2 followed by a subsequent confirmatory PSA &gt;= 0.2&#xD;
             clinically suspicious for biochemically recurrent disease&#xD;
&#xD;
          -  If the patients were previously taking androgen deprivation therapy (ADT), it should&#xD;
             be discontinued at least 12 weeks prior to the study&#xD;
&#xD;
          -  Patient willing to provide signed informed consent and willing to comply with all&#xD;
             required study schedule events, where safe and feasible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any medical condition or circumstance that the investigator believes may&#xD;
             compromise the data collected or lead to a failure to fulfil the study requirements&#xD;
&#xD;
          -  Patients who are planned to have an Iodinated contrast agent with computed tomography&#xD;
             (CT) or gadolinium based contrast agent with MRI or other PET radiotracer &lt; 24 hours&#xD;
             prior to the PET scan&#xD;
&#xD;
          -  Patients with contraindication to undergo MRI&#xD;
&#xD;
          -  Patients with extreme claustrophobia&#xD;
&#xD;
          -  Patients with prior allergy to MRI contrast agent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devaki Shilpa S Surasi</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devaki Shilpa S. Surasi</last_name>
      <phone>713-792-6536</phone>
      <email>dssurasi@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Devaki Shilpa S. Surasi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

